Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer

被引：0
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 01期
关键词：
D O I：
10.1016/j.juro.2016.10.035
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [21] Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).
    Veccia, Antonello
    Burgio, Salvatore Luca
    Di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Aieta, Michele
    Zustovich, Fable
    Mattioli, Rodolfo
    Mansueto, Giovanni
    Facchini, Gaetano
    Procopio, Giuseppe
    D'Angelo, Alessandro
    Spizzo, Gilbert
    Donini, Maddalena
    Bortolus, Roberto
    Vicario, Giovanni
    Zucali, Paolo A.
    Basso, Umberto
    Lo Re, Giovanni
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [22] Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Huang, Ahong
    Wang, Li
    Baser, Onur
    Miao, Raymond
    BJU INTERNATIONAL, 2018, 121 (06) : 871 - 879
  • [23] Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
    Simon Chowdhury
    Anders Bjartell
    Nicolaas Lumen
    Pablo Maroto
    Thomas Paiss
    Francisco Gomez-Veiga
    Alison Birtle
    Gero Kramer
    Ewa Kalinka
    Dominique Spaëth
    Susan Feyerabend
    Vsevolod Matveev
    Florence Lefresne
    Martin Lukac
    Robert Wapenaar
    Luis Costa
    Targeted Oncology, 2020, 15 : 301 - 315
  • [24] Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry
    Chowdhury, Simon
    Bjartell, Anders
    Lumen, Nicolaas
    Maroto, Pablo
    Paiss, Thomas
    Gomez-Veiga, Francisco
    Birtle, Alison
    Kramer, Gero
    Kalinka, Ewa
    Spaeth, Dominique
    Feyerabend, Susan
    Matveev, Vsevolod
    Lefresne, Florence
    Lukac, Martin
    Wapenaarls, Robert
    Costa, Luis
    TARGETED ONCOLOGY, 2020, 15 (03) : 301 - 315
  • [25] Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer
    Maroto, Pablo
    Solsona, Eduardo
    Gallardo, Enrique
    Mellado, Begona
    Morote, Juan
    Angel Arranz, Jose
    Gomez-Veiga, Francisco
    Unda, Miguel
    Angel Climent, Miguel
    Alcaraz, Antonio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 100 : 127 - 136
  • [26] Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)
    Caffo, O.
    Maines, F.
    De Giorgi, U.
    Fratino, L.
    Lo Re, G.
    Zagonel, V.
    D'Angelo, A.
    Donini, M.
    Verderame, F.
    Ratta, R.
    Procopio, G.
    Campadelli, E.
    Massari, F.
    Gasparro, D.
    Ermacora, P.
    Messina, C.
    Giordano, M.
    Alesini, D.
    Conteduca, V.
    Veccia, A.
    Galligioni, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 61 - 61
  • [27] Re: Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated with Docetaxel Therapy
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2020, 203 (01) : 10 - 11
  • [28] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
    Brian Schurko
    William K Oh
    Nature Clinical Practice Oncology, 2008, 5 : 506 - 507
  • [30] Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
    Schurko, Brian
    Oh, William K.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (09): : 506 - 507
12345